Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

@article{Takahashi2010InfluenceOC,
  title={Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia},
  author={Naoto Takahashi and Masatomo Miura and Stuart A. Scott and Hideaki Kagaya and Yoshihiro Kameoka and Hiroyuki Tagawa and Hirobumi Saitoh and Naohito Fujishima and Tomoko Yoshioka and Makoto Hirokawa and Kenichi Sawada},
  journal={Journal of Human Genetics},
  year={2010},
  volume={55},
  pages={731-737}
}
Imatinib mesylate (IM) trough concentration varies among IM-treated chronic myeloid leukemia (CML) patients. Although IM pharmacokinetics is influenced by several enzymes and transporters, little is known about the role of pharmacogenetic variation in IM metabolism. In this study, associations between IM trough concentration, clinical response and 11 single-nucleotide polymorphisms in genes involved in IM pharmacokinetics (ABCB1, ABCC2, ABCG2 CYP3A5, SLC22A1 and SLCO1B3) were investigated among… CONTINUE READING
49 Extracted Citations
55 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 49 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 55 references

Similar Papers

Loading similar papers…